Corcept Data Shows Korlym Boosts GLP-1 Efficacy in Hard-to-Treat Diabetes
Event summary
- Corcept presented CATALYST and MOMENTUM trial data at ADA 2026, showing Korlym improved HbA1c and weight metrics in type 2 diabetes patients on GLP-1s.
- 24% of difficult-to-control diabetes patients in CATALYST had hypercortisolism; Korlym reduced HbA1c by 1.3% vs. placebo.
- In GLP-1-treated subsets, Korlym delivered greater benefits: 1.7% HbA1c drop, 6.1 kg weight loss.
- MOMENTUM trial found 27.3% of resistant hypertension patients had hypercortisolism.
The big picture
Corcept's data suggests hypercortisolism is an underdiagnosed factor in treatment-resistant cardiometabolic diseases. The findings position Korlym as a potential adjunct to GLP-1 therapies, which dominate the diabetes market. If adopted, this approach could expand treatment options for patients failing standard therapies, while creating new competitive dynamics in endocrine and metabolic disorder markets.
What we're watching
- Commercial Strategy
- Whether Corcept can position Korlym as a complementary therapy alongside GLP-1s in diabetes management.
- Regulatory Pathways
- The pace at which hypercortisolism screening becomes standard in diabetes and hypertension treatment guidelines.
- Competitive Dynamics
- How established diabetes treatments may adapt to incorporate cortisol modulation insights.